Chemed (CHE) Q2 Earnings: What To Expect

Healthcare services company Chemed Corporation (NYSE:CHE) will be reporting earnings this Tuesday after market close. Here’s what to look for.

Chemed beat analysts’ revenue expectations last quarter, reporting revenues of $657.5 million, up 1.6% year on year. It was a strong quarter for the company, with a beat of analysts’ EPS estimates.

Is Chemed a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, the market is expecting Chemed’s revenue to grow 7.5% year on year, improving from the 3.8% increase it recorded in the same quarter last year.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business will stay the course heading into earnings. Chemed has missed Wall Street’s revenue estimates multiple times over the last two years.

Looking at Chemed’s peers in the healthcare providers & services segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Tenet Healthcare delivered year-on-year revenue growth of 6.8%, beating analysts’ expectations by 3.9%, and UnitedHealth reported flat revenue, topping estimates by 1.2%. Tenet Healthcare traded up 17.2% following the results while UnitedHealth was also up 1.8%.

Read our full analysis of Tenet Healthcare’s results here and UnitedHealth’s results here.

Investors in the healthcare providers & services segment have had steady hands going into earnings, with share prices up 1.3% on average over the last month. Chemed is up 11.1% during the same time and is heading into earnings with an average analyst price target of $474 (compared to the current share price of $511.13).

WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.

This is what the early days of Palantir looked like before it became a giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.